CoChat

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials

Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E. · 2014 · Diabetes, Obesity and Metabolism
Cited by 174

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this reason, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) are currently undergoing large‐scale, long‐term randomized trials specifically designed for cardiovascular outcomes. Aim of the present meta‐analysis of randomized clinical trials is the assessment of the effects of GLP‐1 RA on major cardiovascular events (MACE), mortality and cardiovascular risk factors. Methods: A meta‐analysis was performed including all trials with a duration of at least 6 months, comparing a GLP‐1 RA with a non‐GLP‐1 RA agent in type 2 diabetes. MACE and mortality were retrieved and combined to calculate Mantel–Haenzel odds ratio ( MH‐OR ). Furthermore, data on endpoint systolic and diastolic blood pressure, total and high‐density lipoprotein (HDL) cholesterol and triglyceride were collected. Results: Of 37 selected trials, 33 reported information on MACE , and 25 reported at least one event. The difference in the incidence of MACE between GLP‐1 RA and comparators did not reach statistical significance [ MH‐OR 0.78 (0.54–1.13), p = 0.18]. GLP‐1 RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a non‐significant trend towards reduction in DPP4i ‐controlled studies. No significant effect of GLP‐1 RA was observed on mortality, although a non‐significant favourable trend was observed in comparisons with placebo. Conclusions: The present meta‐analysis confirms the cardiovascular safety of GLP‐1 RA, at least in the short term and in low‐risk individuals. GLP‐1 RA could have a beneficial effect on the incidence of MACE , at least in comparison with placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12175

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 16

  1. 10.1530/EJE-09-0101 · DOI
  2. 10.1155/2012/672658 · DOI · Paper page
  3. Chiquette E, 2012, Chilton R Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers, Vasc Health Risk Manag, 8, 621
  4. 10.1016/j.numecd.2008.08.002 · DOI
  5. 10.1111/j.1463-1326.2010.01345.x · DOI
  6. 10.1038/sj.bjp.0706780 · DOI · Paper page
  7. 10.7326/0003-4819-151-4-200908180-00135 · DOI · Paper page
  8. 10.1016/0197-2456(95)00134-4 · DOI · Paper page
  9. 10.2307/2533446 · DOI · Paper page
  10. 10.1136/bmj.315.7109.629 · DOI · Paper page
  11. 10.1155/2011/215764 · DOI
  12. 10.1177/1479164111408937 · DOI · Paper page
  13. 10.1016/j.numecd.2009.03.021 · DOI · Paper page
  14. 10.1056/NEJM198104023041401 · DOI · Paper page
  15. The MACB Study Group, 1995, Effect of metoprolol on death and cardiac events during a 2‐year period after coronary artery bypass grafting, Eur Heart J, 16, 1825, 10.1093/oxfordjournals.eurheartj.a060835 · DOI
  16. 10.1111/dom.12000 · DOI · Paper page

Cited by

See all 174

Metadata

Authors
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-07-28
Volume
16
Issue
1
Pages
38-47
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1966379378
Cited by
174
References
9
FWCI
22.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1111/dom.12175
The paper
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014). Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.